Cell therapy · developed by Vericel
Autologous cultured chondrocytes on porcine collagen membrane (MACI) is an autologous cellularized scaffold product made from a patient's own cultured cartilage cells. It is used to repair symptomatic full-thickness cartilage defects of the knee, with or without bone involvement, and is studied in osteochondritis dissecans and other articular cartilage disorders of the knee.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 9, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03588975 | Phase 3 | Chondral Defect | Recruiting | VCEL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Articular Cartilage DefectArticular Cartilage Disorder of KneeChondral DefectOsteochondritis Dissecans (OCD)
Updated Nov 1, 2026. Something wrong or missing? Report it on the VCEL page.
See VCEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VCEL catalysts and pipeline →